Cargando…

The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome

BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understa...

Descripción completa

Detalles Bibliográficos
Autores principales: Laborde, Carlos M, Alonso-Orgaz, Sergio, Mourino-Alvarez, Laura, Moreu, José, Vivanco, Fernando, Padial, Luis R, Barderas, María G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451929/
https://www.ncbi.nlm.nih.gov/pubmed/26038678
http://dx.doi.org/10.1186/1477-5956-12-43
_version_ 1782374223428190208
author Laborde, Carlos M
Alonso-Orgaz, Sergio
Mourino-Alvarez, Laura
Moreu, José
Vivanco, Fernando
Padial, Luis R
Barderas, María G
author_facet Laborde, Carlos M
Alonso-Orgaz, Sergio
Mourino-Alvarez, Laura
Moreu, José
Vivanco, Fernando
Padial, Luis R
Barderas, María G
author_sort Laborde, Carlos M
collection PubMed
description BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understanding of the whole atherosclerotic process from atherogenesis to atherothrombosis. In this study, we conducted two different proteomic analyses of peripheral blood plasma from non-ST elevation acute coronary syndrome and ST elevation acute coronary syndrome patients vs healthy controls. RESULTS: Two-dimensional Fluorescence Difference in Gel Electrophoresis and mass spectrometry permitted the identification of 31 proteins with statistical differences (p < 0.05) between experimental groups. Additionally, validation by Western blot and Selected Reaction Monitoring permitted us to confirm the identification of a different and characteristic plasma proteomic signature for NSTEACS and STEACS patients. CONCLUSIONS: We purpose the severity of hypoxia as the cornerstone for explaining the differences observed between both groups.
format Online
Article
Text
id pubmed-4451929
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44519292015-06-03 The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome Laborde, Carlos M Alonso-Orgaz, Sergio Mourino-Alvarez, Laura Moreu, José Vivanco, Fernando Padial, Luis R Barderas, María G Proteome Sci Research BACKGROUND: Acute coronary syndrome is the major cause of death in developed countries. Despite its high prevalence, there is still a strong need for new biomarkers which permit faster and more accurate diagnostics and new therapeutic drugs. The basis for this challenge lay in improving our understanding of the whole atherosclerotic process from atherogenesis to atherothrombosis. In this study, we conducted two different proteomic analyses of peripheral blood plasma from non-ST elevation acute coronary syndrome and ST elevation acute coronary syndrome patients vs healthy controls. RESULTS: Two-dimensional Fluorescence Difference in Gel Electrophoresis and mass spectrometry permitted the identification of 31 proteins with statistical differences (p < 0.05) between experimental groups. Additionally, validation by Western blot and Selected Reaction Monitoring permitted us to confirm the identification of a different and characteristic plasma proteomic signature for NSTEACS and STEACS patients. CONCLUSIONS: We purpose the severity of hypoxia as the cornerstone for explaining the differences observed between both groups. BioMed Central 2014-10-10 /pmc/articles/PMC4451929/ /pubmed/26038678 http://dx.doi.org/10.1186/1477-5956-12-43 Text en © Laborde et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Laborde, Carlos M
Alonso-Orgaz, Sergio
Mourino-Alvarez, Laura
Moreu, José
Vivanco, Fernando
Padial, Luis R
Barderas, María G
The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title_full The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title_fullStr The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title_full_unstemmed The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title_short The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
title_sort plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451929/
https://www.ncbi.nlm.nih.gov/pubmed/26038678
http://dx.doi.org/10.1186/1477-5956-12-43
work_keys_str_mv AT labordecarlosm theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT alonsoorgazsergio theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT mourinoalvarezlaura theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT moreujose theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT vivancofernando theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT padialluisr theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT barderasmariag theplasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT labordecarlosm plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT alonsoorgazsergio plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT mourinoalvarezlaura plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT moreujose plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT vivancofernando plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT padialluisr plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome
AT barderasmariag plasmaproteomicsignatureasastrategictoolforearlydiagnosisofacutecoronarysyndrome